Auson
Latest round
- Series B
Last raised
- Aug 2022
Total raised
- $30M
Investors
- 7
About Auson
Established in 2019 and based in Shanghai, China, Auson operates as a biopharmaceutical developer focuses on the development of the biopharmaceutical for antiviral and vascular disease. The company is headquartered in Shanghai and has a branch office in New Jersey. Dr. Enxian Lu, the founder and CEO of the company, has a Master of Pharmacy from Fudan University, a Master of Biopharmacy from the University of Illinois, and a Doctor of Pharmacy from the University of Minnesota, with over 20 years of experience in MNC pharmaceutical companies and start-ups. The company's main business is the research, development and production of formulation-improving new drugs. The company's self-developed products include patented product ASN001 for the treatment of infantile hemangioma and patented product ASN008 for the treatment of hepatitis B. The products are used in the field of pediatrics, vascular diseases and antiviral.
Who invested in Auson
7 investors across 3 rounds
See all investors in Auson
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Auson
Who invested in Auson?
Auson has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Auson raised?
Auson has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Auson last raise money?
Auson's most recent round on record is a Series B, in Aug 2022.
What does Auson do?
Established in 2019 and based in Shanghai, China, Auson operates as a biopharmaceutical developer focuses on the development of the biopharmaceutical for antiviral and vascular disease.
Where is Auson headquartered?
Auson is headquartered in Shanghai, China.
Which VCs invest in companies like Auson?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Auson's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Auson? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.